For all our partnerships, we believe in the strength of flexibility and collaboration

Ubiquigent is focused on the exploitation of DUB enzymes and the UPS for drug discovery

As pioneers in this field, we have developed not only an extensive drug discovery platform but also a growing collection of novel compounds that could be developed as DUB inhibitors, DUB-targeting PROTACs or DUBTACs. Through our network of academic partners, collective experience in protein degradation-focused drug discovery, and deep knowledge of ubiquitin system assays and medicinal chemistry, Ubiquigent™ scientists complement customers’ disease-specific expertise to help in the discovery of genuine drug candidates.

Our flexible, collaborative approach has allowed us to build an unrivalled track record as the partner chosen by many leading industry companies and academic organisations to support their deubiquitinase (DUB)-focused drug discovery programmes.

Our partnerships range from strategic and commercial to bespoke CRO and licensing agreements.

If you are also seeking to exploit DUBs and the ubiquitin-proteasome system (UPS) for the development of novel therapeutics, we would welcome the opportunity to explore how we could harness our platform, capabilities, and assets in partnership with you.

Our flexible approach to partnerships ranges from strategic and commercial to CRO and licencing agreements
Contact us for more information on partnering opportunities

Chemistry expertise to design novel compounds

Proprietary DUB-targeting compounds

Novel compounds to provide new starting points for DUB-focused drug discovery programmes

Ubiquigent has a growing collection of novel DUB-targeting compounds that have been evaluated across our suite of comprehensive biochemical and cellular assays. These compounds represent a valuable resource for identifying new starting points for DUB-focused drug discovery programmes.

Highly experienced chemists in DUB drug discovery

Our chemists have worked on the design and development of DUB-binding ligands for our internal pipeline and on behalf of our clients

Ubiquigent chemists are experienced at applying computational and medicinal skills to the design of DUB ligands, encompassing covalent and non-covalent compounds, and compounds with an allosteric mechanism of action. They also have substantial experience in developing orally bioavailable heterobifunctional molecules.

Access to a range of relevant technologies through our growing network of collaborators and industry experts, including in structural biology

Ubiquigent has established a network of academic and industrial partners to augment our own experience, including structural biology, mass spectrometry and individual DUB target-based expertise. These existing partnerships alongside new collaborations, as appropriate, can be leveraged to offer our clients an even more comprehensive DUB-focused partnership.